Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Investigating The Role of FKBP1A Mutations In Mediating Rapamycin- and Rapalog-Resistance
EF 2023-24
Résumé
Chemotherapy, a widely administered cancer treatment, faces a dilemma—the effort to eliminate cancer cells often jeopardizes healthy cells. Resistance to chemotherapy compounds increases this challenge, leading to the exclusive targeting of healthy cells and severely impacting patient outcomes. Cancer cells develop resistance through their rapid mutational rates, particularly in proteins responding to drugs, preventing effective binding and resulting in drug resistance.
A valuable model for studying this resistance is rapalogs, derivatives of rapamycin like everolimus and temsirolimus, used against breast and renal cancers. However, these drugs can prove ineffective due to mutations in their immediate downstream target, FKBP1A, hindering drug binding. My research aims to elucidate the impact of FKBP1A mutations preventing binding to rapamycin, everolimus, and temsirolimus.
Utilizing a yeast model with the analogous gene FPR1, involved in similar signaling cascades, I will introduce the human FKBP1A gene and its variants into the yeast genome. Monitoring yeast growth in the presence of rapalogs, which inhibit growth, will reveal the resistance conferred by specific FKBP1A variants. If normal growth occurs despite rapalogs, it indicates resistance.
Identifying clinically significant variants will enable genetic profiling of tumors before treatment, providing clinicians with the resources to deliver more effective options. This approach enhances patient prognoses by tailoring treatments to individual genetic profiles, bridging the gap between chemotherapy and precision medicine.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505881
Name
Bhachu Keerath
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating The Role of FKBP1A Mutations In Mediating Rapamycin- and Rapalog-Resistance
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cancer Therapy; Chemotherapy; Drug-Resistance; Everolimus; Mutations; Precision Medicine; Rapamycin; Temsirolimus
Abstract
Chemotherapy, a widely administered cancer treatment, faces a dilemma—the effort to eliminate cancer cells often jeopardizes healthy cells. Resistance to chemotherapy compounds increases this challenge, leading to the exclusive targeting of healthy cells and severely impacting patient outcomes. Cancer cells develop resistance through their rapid mutational rates, particularly in proteins responding to drugs, preventing effective binding and resulting in drug resistance.
A valuable model for studying this resistance is rapalogs, derivatives of rapamycin like everolimus and temsirolimus, used against breast and renal cancers. However, these drugs can prove ineffective due to mutations in their immediate downstream target, FKBP1A, hindering drug binding. My research aims to elucidate the impact of FKBP1A mutations preventing binding to rapamycin, everolimus, and temsirolimus.
Utilizing a yeast model with the analogous gene FPR1, involved in similar signaling cascades, I will introduce the human FKBP1A gene and its variants into the yeast genome. Monitoring yeast growth in the presence of rapalogs, which inhibit growth, will reveal the resistance conferred by specific FKBP1A variants. If normal growth occurs despite rapalogs, it indicates resistance.
Identifying clinically significant variants will enable genetic profiling of tumors before treatment, providing clinicians with the resources to deliver more effective options. This approach enhances patient prognoses by tailoring treatments to individual genetic profiles, bridging the gap between chemotherapy and precision medicine.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bhachu, Keerath
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~